Alumis Plunges 55% as Lupus Drug Fails Phase 2b, But Subgroup Data Offers Path Forward
ALMS has more than doubled off its 52-week low of $3.76 on elevated volume (10× avg).
Summary
Alumis shares are down 54.84% to $9.85 after the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus missed its primary and secondary endpoints in the overall population. The failure follows the earlier Reuters report this morning, but this article adds critical detail: a prespecified subgroup of patients with high interferon gene signature met the primary endpoint and key secondary measures, and these patients were unexpectedly under-represented in the trial. Pharmacodynamic data confirmed strong dose-dependent target engagement, and the drug was well tolerated with no new safety signals. Management sees a clear path to Phase 3 in the high-signature subgroup, but the market is pricing in significant uncertainty. The company's $502.3M cash position provides runway into 2027, but the lupus program's future now hinges on regulatory engagement and a redesigned Phase 3. Watch for management commentary on the earnings call and any FDA feedback on the subgroup strategy.
At the time of this announcement, ALMS was trading at $9.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.76 to $31.35. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.